About Loxapine
In 1975 Loxitane© (loxapine succinate) capsule formulation came out, offering a new choice in first-generation antipsychotic medications. While its molecular structure is nearly identical to clozapine, a second-generation or “atypical” medication, loxapine was found less associated with heart injuries than other antipsychotics, and less likely to cause the drooling effect that can make antipsychotic therapy undesirable. Neither loxapine nor clozapine are considered 1st-line treatments but are turned to when other treatments were found unsatisfactory. Loxapine has been described as having some “second-generation” characteristics, though it is classed as a “first-generation” or “typical” antipsychotic. 1,7,23
Since 1975 new versions have been produced including an oral liquid version, (Loxitane C©), an injectable form, (Loxitane IM©), and an inhalent powder form of loxapine, (Adasuve©). Audsuve is an extremely fast-acting drug (less than 10 minutes) used to quell high-level agitation in persons with schizophrenia that could endanger one’s own or another’s life. Loxapine is not approved for dementia patients presenting with agitation.1,13
All antipsychotic medications can cause adverse effects which can begin to outweigh the benefits for an individual. The phenomenon known as medication tolerance, where the drug stops working, is another challenge in treatment. Although loxapine may have been the correct treatment option at the time of a severe crisis, after a patient has stabilized, it may be time to consider other treatment options.
A diagnosis of schizophrenia and similar disorders has been confounded by many factors historically, including a poor understanding of the causes of the condition, often resulting in misdiagnosis, and failed treatment methods. Once viewed as a life-long physical deterioration of the brain, modern research has illuminated a more complete understanding of schizophrenia and psychosis, and how risk factors such as diet, toxin exposures, genetic factors, marijuana use, childhood trauma, and others can precipitate such disorders. 3,5,8
Loxapine withdrawal may be an opportunity to initiate a treatment plan that can make more effective treatment options possible. We believe antipsychotic withdrawal is best done in an attentive and medically monitored setting to ensure the safety and comfort of the patient. Adequate support must also be in place to allow for a comprehensive and effective horizon of treatment. Completely eliminating antipsychotic medication may take a considerable amount of time, months, or even years, and should always be done with competent medical support, adequate therapies, and compassionate guidance. 4,6
Loxapine Withdrawal and Neuroadaptation
Antipsychotic drugs influence certain chemical receptors located in the brain and CNS. An antipsychotic drug is thought to act something like a tap, so the expression of certain (natural) chemicals can be shut down or decreased. To compare, in stimulants, the tap might be opened to increase the flow of certain neurotransmitters. In the case of psychosis and symptoms of schizophrenia, restricting dopamine expression is the job of antipsychotic medication.
Depending on the drug, different receptors may be affected. In the case of loxapine, dopamine and possibly others are disabled, or changed, resulting in calming sedation, and quieting unwanted symptoms such as hallucinations, and agitation. By contrast, a torrent of chemicals is unleashed when an antipsychotic drug is withdrawn too abruptly. The faster the withdrawal, the worse the gush. You want to go slow and avoid such an overwhelming catastrophe.
As with all antipsychotic medications, loxapine withdrawal (especially when attempted too quickly) is commonly associated with rebound symptoms that can be as intense or more intense than the original symptoms prior to medication. We have found that this tendency is primarily seen where the withdrawal is too fast, and most commonly, where preparation steps have been omitted or skimped. More information on preparing for loxapine withdrawal is given further on in this article.
In addition to rebound symptoms, antipsychotic withdrawal symptoms in general can be identified as newly emerging symptoms that were not present during drug treatment. The mechanics of how and why withdrawal symptoms occur is not fully understood, but the general consensus is that neuroadaptation plays a major role. Neuroadaptation occurs over time, so one has to discontinue the drug slowly enough so as to not cause a catastrophe of rebound or other symptoms.9,10